Jiangsu Wuzhong Pharmaceutical Group Corporation announced a equity round of funding for gross proceeds of CNY 340 million with existing investor JiangSu WuZhong Pharmaceutical Development Co., Ltd. on January 5, 2022. As a part of the round, the registered capital of the company will increase from CNY 400 million to CNY 740 million. Post the capital increase, the investor will retain its 100% stake in the company.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
9.86 CNY | +0.10% | +1.86% | +19.95% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+19.95% | 959M | |
+48.79% | 781B | |
+41.86% | 639B | |
+19.43% | 330B | |
+7.18% | 293B | |
+17.58% | 248B | |
+0.20% | 221B | |
+11.54% | 217B | |
+4.53% | 162B | |
-3.92% | 157B |
- Stock Market
- Equities
- 600200 Stock
- News JiangSu WuZhong Pharmaceutical Development Co., Ltd.
- Jiangsu Wuzhong Pharmaceutical Group Corporation announced that it expects to receive CNY 340 million in funding from JiangSu WuZhong Pharmaceutical Development Co., Ltd.